Clinical trial · no report yet · Phase not applicable

CARES-005 trial: what clinicians have said so far

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

NCT04559607 ↗
Unknown
Zhongda Hospital
Standard size, estimated: 151–300 verified statements

We haven't built an HCP commentary report on CARES-005 (camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on CARES-005 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
11 posts on X
1 YouTube video

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials
Phase: Phase not applicable
Status: Unknown
Conditions: Hepatocellular Carcinoma
Interventions: Camrelizumab; TACE; Apatinib
Arms: Experimental group: TACE+Camrelizumab+Apatinib · Experimental
Control group: TACE · Active comparator
Enrollment: 188
Primary outcomes: Progression-free survival (PFS) by investigator
Sponsor: Zhongda Hospital
Start: Sep 11, 2020
Primary completion: Aug 31, 2024 (estimated)
Results posted: No
Registry record: NCT04559607 · updated Dec 18, 2023

Publications

linked from the registry

Zhu HD, Fan WJ, Zhao C, Wang S, Li YL, Jin ZC, Zhang ZW, Guo JH, Cheng HT, Zhang Q, Lu J, Zeng YY, Lv WF, Xu H, Shao HB, Xu WG, Zhao XY, Gu SZ, Lin HL, Zheng WH, Piao LZ, Song YS, Zhao JB, Wang YC, Hou ZG, Sun Y, Guan N, Huang M, Yang WZ, Ji JS, Teng GJ. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. J Clin Oncol. 2026 Apr 10;44(11):959-969. doi: 10.1200/JCO-25-01796. Epub 2026 Feb 24. PubMed 41734362

Get this report

Standard

Report, built on orderBuilt within 24 hours of confirming your order: $1,250

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on CARES-005 so far

Reports on the same drug or indication

The trial

Publications